价值深耕，全球突破：中国生物医药创新观察（2026.1.26-2026.1.30）：医疗与消费周报-20260202

Investment Insights - The report highlights that the pharmaceutical index observed negative returns across six sub-industries during the week [1] - China's biopharmaceutical industry is transitioning from a "rapid expansion" phase (1.0 era) to a "value and global competitiveness" phase (2.0 era), marking its emergence as the second-largest new drug launch market globally [1][6] - By 2025, the external licensing transaction value is expected to exceed $50 billion, with China establishing a leadership position in disruptive technologies such as targeted protein degradation [1][6] Industry Overview - China accounted for 18% of the global share of new molecular entities (NME) launched in 2024, ranking second worldwide [6] - The number of new drug pipelines in China represents approximately 30% of the global total, maintaining its position as the second-largest globally [6] - In the targeted protein degradation (TPD) field, China contributes 38% of global research papers and 37% of patents, with around 30% of the 484 TPD candidates in development originating from China [6] Market Performance - The report notes that the biopharmaceutical sector's performance was mixed, with traditional Chinese medicine and biological products experiencing declines of -1.94% and -2.50%, respectively [8] - The highest valuation levels were recorded for biological products (91.41 times) and chemical pharmaceuticals (79.85 times), while traditional Chinese medicine and pharmaceutical commerce had lower valuations of 31.70 times and 22.42 times, respectively [8] Future Outlook - The industry is expected to face both opportunities and challenges as it enters the new "14th Five-Year Plan" cycle, with a trend towards "the rich getting richer" and a focus on source innovation and global expansion [7] - Key challenges include resource misallocation due to concentrated research on popular targets, high R&D costs, and the need for improved international capabilities among many companies [7]